Off-label use of rituximab in a tertiary Queensland hospital: ORIGINAL ARTICLE

Internal Medicine Journal

Volumn 40, Issue 6, 2010, Pages 443-452

  Butterly, S J ^a   Pillans, P ^a   Horn, B ^a   Miles, R ^a   Sturtevant, J ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Rituximab off label use

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BASILIXIMAB; CISAPRIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; ARTICLE; AUSTRALIA; AUTONOMIC NEUROPATHY; CANCER RISK; CEREBELLUM DEGENERATION; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DISEASE COURSE; DRUG COST; DRUG INDICATION; DRUG SAFETY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MEMBRANOUS GLOMERULONEPHRITIS; MYASTHENIA GRAVIS; NEOPLASM; NEUTROPENIA; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT COUNSELING; PLASMAPHERESIS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SHRINKING LUNG SYNDROME; SJOEGREN SYNDROME; SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TREATMENT FAILURE; TREATMENT RESPONSE; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HOSPITALIZATION; HOSPITALS, PUBLIC; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; OFF-LABEL USE; QUEENSLAND; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953857521     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01988.x     Document Type: Article

References (43)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 : 435 445.
2. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006 6 : 859 866.
3. Roche. Mabthera (Rituximab) Product Information Approved August 2006, Vol. 2006.
4. Gottenberg J-E, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune disease. Ann Rheum Dis 2005 64 : 913 920.
5. Bayry J, Lacoix-Desmazes D, Kazatchkine M, Kaveri S. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic disease: rationale and mechanisms of action. Nat Clin Pract Rheumatol 2007 3 : 262 72.
6. Sharma R, Koller L, Barclay P, Liddle C. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales. Intern Med J 2007 37 : 569 571.
7. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007 20 : 277 287.
8. Silverman G. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005 52 : 371 377.
9. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006 185 : 544 8.
10. Campbell T, Gandecha K, Gazarian M, Graudins L, Kelly M, McCahon E et al. for NSW Therapeutic Advisory Group Inc, 2003. Off-label use of registered medicines and use of medicines under the personal importation scheme in NSW public hospitals (Discussion Paper). 2003.
11. van Vollenhoven RF, Gunnarsson I, Weilin-Henriksson E, Sundelin B, Österborg A, Jacobson SH, Klareskog L. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 204 : 423 427.
12. Jacobson SH, van Vollenhonve R, Gunnarsson I. Rituximab-induced long-term remission in membranous lupus nephritis. Nephrol Dial Transplant 2006 21 : 1742 1743.
13. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006 8 : R83.
14. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000 165 : 5970 5979.
15. Sarwal M, Chua M-S, Kambham N, Hsieh S-C, Satterwhite BS, Masek MS et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003 349 : 125 138. (Pubitemid 36818782)
16. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplantation rejection. Am J Transplant 2004 4 : 996 1001.
17. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, Kling KE et al. Plasmapharesis, CMV hyperimmune globulin and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004 4 : 1315 1322.
18. Sawada T, Fuchinoue S, Kawase T, Kubota K, Teraoka S. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004 18 : 254 260.
19. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003 76 : 730 743.
20. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for post transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005 20 : 1660 1663.
21. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006 354 : 1961 1962.
22. Gossmann J, Scheuermann E-H, Porubsky S, Kachel H-G, Geiger H, Hauser IA. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 2007 20 : 558 562.
23. Benz K, Dötsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004 19 : 794 797.
24. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008 8 : 222 227.
25. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001 7 : 365 368.
26. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007 254 : 986 969.
27. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006 33 : 575 580.
28. Wylam PM, Anderson ME, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003 143 : 674.
29. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992 327 : 1490 1495.
30. Sansonno D, Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003 101 : 3818 3826.
31. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003 101 : 3827 3834.
32. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007 125 : 30 3.
33. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004 77 : 171 176.
34. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H-M. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004 124 : 787 795.
35. Fakhouri F, Vernant J-P, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005 106 : 1932 1937.
36. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005 106 : 925 928.
37. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the haemolytic-uremic syndrome. N Engl J Med 1998 339 : 1578 1584. (Pubitemid 28536132)
38. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008 141 : 149 169.
39. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002 346 : 995 1008.
40. Brændstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenia purpura. Am J Hematol 2005 78 : 275 280.
41. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V et al. Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006 34 : 571 572.
42. Zhou Z, Yang R. Rituximab for treatment of chronic refractory idiopathic thobocytopenic purpura. Crit Rev Oncol Hematol 2008 65 : 21 31.
43. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146 : 25 33.